holybuvir (SH-229) / Nanjing Sanhome Pharma - LARVOL DELTA

Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects. (PubMed, Antimicrob Agents Chemother) - "The favorable PK and safety results support the further development of holybuvir for patients with HCV. (This study was registered at Chinadrugtrials.org under identifier CTR20170859.)."

Journal • PK/PD data • Hepatitis C • Hepatology • Infectious Disease • Inflammation

[VIRTUAL] SH229 plus daclatasvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 study (EASL-ILC 2021) - "Treatment with the pan-genotypic regimen of SH229 plus daclatasvir for 12 weeks was highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting this regimen could be a promising option for HCV treatment in China irrespective of genotype."

Clinical • P3 data • Dyslipidemia • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders

[VIRTUAL] A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection (EASL-ILC-I 2020) - "Once-daily oral administration of SH229 plus daclatasvir were highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting SH229 could be a promising drug candidate for HCV treatment in China irrespective of genotype."

Clinical • P2 data • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • Infectious Disease

A phase 2, open-label study of pan-genotype regimen of sh229 plus daclatasvir in chinese patients with chronic hepatitis c virus infection (EASL-ILC 2020) - No abstract available

Clinical • P2 data